WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsParasitic infections
Open this folder and view contentsInsect and arachnid bites and stings
Open this folder and view contentsSuperficial fungal infections
Open this folder and view contentsSubcutaneous fungal infections
Open this folder and view contentsBacterial infections
Open this folder and view contentsViral infections
Open this folder and view contentsEczematous diseases
Open this folder and view contentsScaling diseases
Open this folder and view contentsPapulosquamous diseases
View the documentCutaneous reactions to drugs
Open this folder and view contentsPigmentary disorders
Open this folder and view contentsPremalignant lesions and malignant tumours
Open this folder and view contentsPhotodermatoses
Open this folder and view contentsBullous dermatoses
View the documentAlopecia areata
View the documentUrticaria
Open this folder and view contentsConditions common in children
View the documentAcne vulgaris
View the documentPruritus
View the documentTropical ulcers
Close this folderAntimicrobial drugs
View the documentAciclovir
View the documentBenzylpenicillin
View the documentClioquinol
View the documentErythromycin
View the documentMethylrosanilinium chloride (gentian violet)
View the documentNeomycin + bacitracin
View the documentTetracycline
View the documentTiabendazole
Open this folder and view contentsAntifugal drugs
Open this folder and view contentsAntiseptic agents
Open this folder and view contentsKeratoplastic and keratolytic agents
Open this folder and view contentsScabicides and pediculicides
Open this folder and view contentsAnti-inflammatory and antipruritic drugs1
Open this folder and view contentsAntiallergics and drugs used in anaphylaxis
Open this folder and view contentsUltraviolet radiation-blocking agents (sunscreens)
Open this folder and view contentsMiscellaneous drugs
Open this folder and view contentsAnnex
View the documentSelected WHO Publications of Related Interest
View the documentBack cover
 

Methylrosanilinium chloride (gentian violet)

Aqueous solution, 0.5%

General information

Methylrosanilinium chloride is a triphenylmethane dye. It inhibits the growth of many fungi including yeasts and is also active against some Gram-positive bacilli.

Methylrosanilinium chloride is widely available and relatively inexpensive.

Clinical information

Uses

Treatment of:

• superficial dermatophyte infections
• cutaneous, mucocutaneous and vaginal candidosis
• intertriginous seborrhoeic dermatitis
• superficial bacterial pyodermas.

Dosage and administration

Adults and children: topical application twice or three times daily produces significant clearing of responsive lesions within a few days.

Contraindications

Known hypersensitivity to the dye.

Precautions

Treatment should be withdrawn immediately should a rash or any other signs of hypersensitivity occur. Patients should be warned that temporary staining of the skin and permanent staining of clothing may occur.

Use in pregnancy

Safe use in pregnancy has not been established. Treatment should be deferred until after delivery.

Adverse effects

Methylrosanilinium chloride is usually well tolerated. Occasionally severe irritation occurs, which may necessitate discontinuation of treatment.

Storage

The solution should be stored in tightly closed containers, protected from light.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014